New data from Part A of Phase 2b/3 trial of izokibep in Hidradenitis Suppurativa demonstrated improvements in number of draining tunnels in two-thirds of patients as early as week 4; the placebo-controlled Part B remains on track for top-line data in the third quarter 2023.
Enrollment completed in Phase 2b/3 randomized controlled trial of izokibep in Psoriatic Arthritis; top-line data now accelerated to first quarter 2024 from mid-2024.
Strong cash position of
Company to host conference call and webcast at
“The first half of 2023 has been productive and rewarding as we marked a number of clinical and corporate milestones supporting our mission to identify, acquire and accelerate the development and commercialization of transformative medicines for patients,” said
“In addition to our consistent clinical progress, we continue to build out our exceptional senior leadership team with the addition of veteran immunology sales and marketing leader
Recent Highlights and Upcoming Milestones
Izokibep
Izokibep is a small protein therapeutic designed to inhibit IL-17A with high potency and small molecular size, approximately 1/10th the size of a monoclonal antibody. Our recent data in Hidradenitis Suppurativa (HS) and Psoriatic Arthritis (PsA) demonstrate – in two independent data sets across two indications – the potential for resolution of disease in difficult-to-treat tissues, and that improves over time. Trials designed for the potential to be part of registrational packages are underway in moderate-to-severe HS, PsA and uveitis, with plans to initiate an additional Phase 3 program in axial spondyloarthritis (AxSpA).
- A new analysis from Part A of the Phase 2b/3 trial in HS suggests that treatment with izokibep results in improvement of at least one draining tunnel as early as week 4 in two-thirds of continuing patients. Week 4 was the first timepoint assessed and this result remained consistent through week 12. Furthermore, half of continuing patients improved by at least two draining tunnels by week 8 and remained consistent through week 12. The speed of response, as well as the magnitude of response at the later time points, is a promising development. It is important to note that this analysis is based off a small dataset with numbers of patients in the high single digit to low double digits. Additional understanding of izokibep’s impact on draining tunnels will be informed by the Part B data set.
- Enrollment of the double-blind, placebo-controlled Part B of the Phase 2b/3 trial evaluating izokibep in HS completed ahead of schedule, accelerating anticipated top-line results into the third quarter 2023.
- Enrollment of the double-blind, placebo-controlled Part B of the Phase 2b/3 trial evaluating izokibep in HS completed ahead of schedule, accelerating anticipated top-line results into the third quarter 2023.
- Based on the results seen in the open-label Part A of the trial as presented at AAD in
March 2023 , we remain focused on resolution of disease as approximated by high orders of response such as HiSCR100. HiSCR100 is a stringent measure of disease control in HS as it requires the same individual to achieve both abscess/nodule resolution without formation of new draining tunnels. We believe that full control of active inflammation enables the early improvements observed in the number of draining tunnels in Part A. - Also during the quarter, an independent Data Monitoring Committee (DMC) conducted a pre-planned review of unblinded efficacy and safety data from Part B of the P2b/3 trial in HS and confirmed the dose of 160mg QW for the second Phase 3 trial in HS. While the company remains blinded to the data, this confirmation is consistent with the understanding that higher exposures are required in HS and aligns with our hypothesis that the high potency and small size of izokibep could lead to clinically meaningful differentiated benefits.
- With the dose confirmed in May, we dosed the first patient in the second HS Phase 3 trial in June, and that trial continues to actively enroll.
- With the dose confirmed in May, we dosed the first patient in the second HS Phase 3 trial in June, and that trial continues to actively enroll.
- In April, the Company reported 46-week results from the Phase 2 trial in PsA that showed continued, deepening improvements beyond 16 weeks across key manifestations of the disease. Of participants receiving izokibep 80 mg Q2W, 79% achieved ACR50 response versus 52% at week 16 and even higher measures of clinical response – including significant control or resolution of disease – were observed with 50% achieving ACR70 response, 71% achieving PASI100 response, and 89% achieving enthesitis resolution. This was predicted by internal modeling that suggested the magnitude of clinical response would continue to increase with longer duration of treatment. The model also predicts further differentiation may be achieved with increasing dose levels, which we are testing in the ongoing Phase 2b/3 trial in PsA.
- Enrollment in the PsA Phase 2b/3 trial has been completed, and top-line results are now anticipated to be accelerated into first quarter 2024 from mid-2024.
- Enrollment in the PsA Phase 2b/3 trial has been completed, and top-line results are now anticipated to be accelerated into first quarter 2024 from mid-2024.
- A Phase 2b/3 trial evaluating izokibep in uveitis is enrolling. Previously reported data for secukinumab have validated the inhibition of IL-17A in uveitis by demonstrating a clinical response with IV levels of exposure. Izokibep can achieve secukinumab IV level exposures with a single subcutaneous injection. This provides the potential to unlock inhibition of IL-17A as an approach to treating uveitis where significant unmet need remains.
- The Company also plans to initiate a Phase 3 program to evaluate izokibep for the treatment of AxSpA in 2024. Enthesitis is a central feature of AxSpA, and we believe the rates of enthesitis resolution demonstrated in the Phase 2 PsA trial suggest the potential for clinically meaningful, differentiated benefits for patients with this disease.
Lonigutamab
Lonigutamab is a subcutaneously delivered anti-IGF-1R monoclonal antibody with high potency in development for thyroid eye disease (TED). The understanding of TED as a chronic inflammatory condition continues to evolve, especially with recent studies demonstrating efficacy in subjects considered chronic rather than acute. Recent updates from the FDA to the warnings and precautions of the teprotumumab label also highlight hearing impairment as a serious, potentially permanent side effect. We hypothesize that the characteristics of lonigutamab can optimize clinical response by maintaining minimum drug levels needed to achieve improved depth and durability of response, limit safety liability – including hearing impairment/loss – potentially associated with high maximum drug concentrations, and maximize patient convenience through single injection subcutaneous delivery.
- The Phase 1/2 Proof-of-Concept (PoC) trial of lonigutamab delivered subcutaneously in TED patients is ongoing and the Company expects to announce top-line results by late 2023/early 2024.
SLRN-517
SLRN-517 is a fully human monoclonal antibody targeting c-KIT, the inhibition of which reduces mast cell proliferation and activity in various allergy and inflammatory diseases. The high potency and fully human design of SLRN-517 is hypothesized to enable greater exposures, reduce potential for immunogenicity and therefore potentially limit acute reactions to the drug itself, and rapidly deplete mast cells while limiting opportunity for other effects of inhibiting c-KIT in other sensitive tissues (spermatogenesis, hair color, hematopoietic cells (neutropenia)). In addition to chronic urticaria (CU), SLRN-517 also has the potential to address several other mast cell-driven disorders such as prurigo nodularis, bullous pemphigoid and eosinophilic esophagitis.
- The Phase 1/2 PoC trial of SLRN-517 is ongoing and will include healthy volunteers and CU patients. The Company expects to announce top-line results in the second half of 2024.
Leadership Updates
The Company announced the appointment of veteran immunology leader
The Company also announced that
Second Quarter 2023 Financial Highlights
Initial Public Offering
On
Cash Position: Cash, cash equivalents and short-term marketable securities totaled
R&D Expenses: Research and development expenses were
G&A Expenses: General and administrative expenses were
Net Loss: Net loss totaled
Conference Call Information
ACELYRIN will host a conference call and webcast today,
About ACELYRIN
ACELYRIN, INC. (Nasdaq: SLRN) is a
About Izokibep
Izokibep is a small protein therapeutic designed to inhibit IL-17A with high potency through tight binding affinity, the potential for robust tissue penetration due to its small molecular size, about one-tenth the size of a monoclonal antibody, and an albumin binding domain that extends half-life. Clinical trial data supports the hypothesis that these unique characteristics of izokibep may provide clinically meaningful and differentiated benefits for patients, including resolution of key manifestations of disease. Izokibep is being evaluated in multiple late-stage trials in moderate-to-severe hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and uveitis, with plans to initiate an additional Phase 3 program in axial spondyloarthritis (AxSpA).
Forward Looking Statements
This press release contains forward-looking statements including, but not limited to, statements related to ACELYRIN’s expectations regarding its cash runway and ability to fund several key milestones; the advancement of ACELYRIN’s programs and ability to accelerate the development and delivery of transformative medicines; anticipated development activities including the planned initiation of clinical trials, establishment of proof of concept and/or the availability of clinical data; the therapeutic potential of ACELYRIN’s product candidates including its ability to offer clinically meaningful, differentiated benefits for patients that may include resolution of key manifestations of disease and limit safety liability; the potential commercial launch of ACELYRIN’s product candidates; and other statements that are not historical fact. These forward-looking statements are based on ACELYRIN’s current plans, objectives and projections, and are inherently subject to risks and uncertainties that may cause ACELYRIN’s actual results to materially differ from those anticipated in such forward-looking statements. Such risks and uncertainties include, without limitation, those associated with the successful completion of development and regulatory activities with respect to ACELYRIN’s product candidates; maintaining and defending intellectual property protection; delays or failures to secure adequate supply of its product candidates; ACELYRIN’s failure to realize the expected benefits of its acquisition of additional programs; legal proceedings, government investigations or other actions; macroeconomic conditions; market volatility; and other risks and uncertainties affecting ACELYRIN including those described from time to time under the caption “Risk Factors” and elsewhere in ACELYRIN’s current and future reports filed with the
Consolidated Statements of Operations and Comprehensive Loss | |||||||||||||||
(in thousands, except share and per share data) | |||||||||||||||
(in thousands) | |||||||||||||||
Three months ended | Six Months Ended | ||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||
Operating expenses | |||||||||||||||
Research and development | $ | 30,030 | $ | 12,710 | $ | 197,950 | $ | 25,713 | |||||||
General and administrative | $ | 12,666 | $ | 2,176 | $ | 24,579 | $ | 5,258 | |||||||
Total operating expenses | 42,696 | 14,886 | 222,529 | 30,971 | |||||||||||
Loss from operations | (42,696) | (14,886) | (222,529) | (30,971) | |||||||||||
Change in fair value of derivative liability | 10,144 | - | 10,291 | - | |||||||||||
Interest income | 6,685 | 413 | 9,984 | 413 | |||||||||||
Other expense, net | (172) | (1) | (235) | (1) | |||||||||||
Net loss | (26,039) | (14,474) | (202,489) | (30,559) | |||||||||||
Other comprehensive gain (loss) | |||||||||||||||
Unrealized gain (loss) on short-term marketable securities, net | 44 | (138) | 130 | (138) | |||||||||||
Total other comprehensive gain (loss) | 44 | (138) | 130 | (138) | |||||||||||
Net loss and other comprehensive loss | $ | (25,995) | $ | (14,612) | $ | (202,359) | $ | (30,697) | |||||||
Net loss per share attributable to common stockholders, basic and diluted | $ | (0.40) | $ | (9.12) | $ | (4.71) | $ | (24.54) | |||||||
Weighted-average common shares outstanding, basic and diluted | 65,210,117 | 1,587,471 | 42,974,640 | 1,245,300 | |||||||||||
ACELYRIN, INC. | |||||||
Selected Consolidated Balance Sheet Data | |||||||
(unaudited) | |||||||
(in thousands) | |||||||
2023 | 2022 | ||||||
Cash and cash equivalents | $ | 556,169 | $ | 267,110 | |||
Short-term marketable securities | 266,821 | 47,510 | |||||
Total assets | 835,126 | 319,923 | |||||
Total liabilities | 34,060 | 26,192 | |||||
Accumulated deficit | (309,567) | (107,078) | |||||
ACELYRIN, INC.
Vice President of Investor Relations,
Communications and Corporate Operations
investors@acelyrin.com
media@acelyrin.com
Source:
2023 GlobeNewswire, Inc., source